Capabilities that accelerate discovery and unlock new possibilities

Our Discovery Capabilities

We work across two core areas to unlock new possibilities in early-stage drug discovery — supporting partners through high-impact services and advancing our own innovation and internal pipeline in high-value, underserved disease areas.

Drug Discovery Enablement

Faster, smarter services for pharmaceutical and biotechnology teams

MassAffinity offers a set of specialised products and services to help drug discovery teams tackle their most pressing early-stage discovery challenges — especially where traditional methods fall short. Whether you are working with complex diseases, AI-generated hits or undruggable targets, our platform delivers speed, clarity, and confidence.

Direct Binder Screening


Find compounds that bind your target, label-free


We detect protein–ligand interactions directly under native conditions, helping identify true binders without relying on labels, immobilisation or proxy assay readouts.

Fragment Screening for Weak Binders


Capture early interactions others may miss


We use native mass spectrometry to detect weak, low-molecular-weight binders, supporting early hit discovery and fragment-to-lead strategies for challenging targets.

Macrocycle Sequencing & Deconvolution


Connect complex ligands back to their identity


We use accurate mass, fragmentation and library design information to link peptide and macrocycle signals back to candidate sequences, building blocks or library members. No DNA tags required.

Molecular Glue & PROTAC Screening


Measure induced proximity directly


We detect ligand-induced complex formation, helping evaluate molecular glues, PROTACs and other proximity-inducing molecules through direct observation of ternary complexes.

AI-Predicted Hit Validation


Turn computational predictions into evidence


We experimentally test predicted binders and target–ligand interactions, helping AI-driven teams prioritise the compounds most likely to translate into real discovery progress.

Pooled Library Screening & Hit Deconvolution


Screen more chemical space with fewer bottlenecks


We support multiplexed screening workflows that identify binding signals from complex mixtures while preserving traceability back to candidate compounds or library members.

Therapeutic Advancement & Discovery

Our internal focus on unlocking complex and underserved 
disease areas

Alongside our partner services, we invest in advancing our own IP and early-stage pipeline in areas where traditional tools have failed. Our goal is to build new pathways to treatment — starting with diseases that lack investment, clarity or both.

This work reflects our belief in a systems-level approach to treating complex, underserved conditions.

Platform advancement

Developing native mass spectrometry workflows that reveal how compounds interact with proteins, complexes and pathways in biologically relevant systems.

Applied Interactomics

Building discovery approaches for diseases driven by multiple interacting pathways, where single-target assumptions and simplified assays can miss important biology.

Multifactorial Disease Discovery

Generating structured experimental interaction datasets that help validate predictions, train models and close the loop between computation and biology.

AI-Ready Discovery Data

Therapeutic advancement

Targeting under-researched conditions such as endometriosis by connecting disease biology, molecular interactions and new therapeutic opportunities.

Women's Health

Advancing discovery in diseases shaped by interacting targets, pathways and patient biology, where conventional reductionist approaches often fall short.

Complex Disease Biology

Building early therapeutic opportunities across multifactorial disease areas, with scope for co-development, data partnerships and discovery-stage partnering.

Pipeline Development & Partnering Opportunities

Our pipeline

Advancing treatments in high-need, underexplored areas

We’re actively building a pipeline of internal research programs focused on complex, underserved diseases. Our emerging pipeline targets key areas including neurological health, women’s health and multifactorial conditions.

MA112
Endometriosis (Undisclosed Target)
Target ID Target validation Hit ID Hit-to-Lead Clinical Trials Regulatory Approval Market Release
MA113
Endometriosis (Undisclosed Target)
Target ID Target validation Hit ID Hit-to-Lead Clinical Trials Regulatory Approval Market Release
MAXXX
Women’s Health (Multifactorial Discovery)
Target ID Target validation Hit ID Hit-to-Lead Clinical Trials Regulatory Approval Market Release
mas spec image (3)